Mylan Collaborated with Atomo Diagnostics for Commercialization of HIV Rapid Diagnostic tests for Low and Middle-Income Countries
Shots:
- Mylan to get exclusive commercialization rights of the product in >100 countries- including Africa- Asia- the Middle East- the Commonwealth of Independent States (CIS) and Latin America. Mylan plans to launch Mylan HIV Self-Test in global markets in 2019
- CE-Marked in-vitro HIV rapid diagnostic tests allow individuals to detect presence or absence of HIV Abs in a single drop of blood obtained from fingertip demonstrating the results in fifteen minutes
- Out of 36.7M population one-third are still undiagnosed and unaware of HIV infection. The tests will allow individuals to self-check in the privacy with simple and accurate device
Ref: Atomo Diagnostics | Image: Helmsleyrashid
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com